EVM
DRNA

Eaton Vance Management’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Eaton Vance Management’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,638
Closed -$67K – 3118
2021
Q1 		$67K Buy
+2,638
New +$67.4K ﹤0.01% 1721

Other funds holding DRNA

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Eaton Vance Management's DRNA Position: Q2 2021 in Review

Eaton Vance Management sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q2 2021, closing a stake of 2,638 shares — an estimated $67K sold.

Eaton Vance Management first reported a position in DRNA in Q1 2021 and held it in 1 quarter. The position peaked at $67K in Q1 2021. 203 funds tracked by Wall St. Rank hold DRNA as of Q2 2021.

  • Eaton Vance Management reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
  • Eaton Vance Management sold 2,638 Dicerna Pharmaceuticals, Inc. shares in Q2 2021, an estimated $67K.
  • Eaton Vance Management first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2021 and held it in 1 quarter.
  • Eaton Vance Management's Dicerna Pharmaceuticals, Inc. position peaked at $67K in Q1 2021.
  • 203 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q2 2021.

Based on Eaton Vance Management's 13F filing for Q2 2021, filed 16 Aug 2021.